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ABSTRACT
A hallmark of cancer cells is the ability to evade the growth inhibitory/pro-
apoptotic action of physiological all-trans retinoic acid (RA) signal, the bioactive 
derivative of Vitamin A. However, as we and others reported, RA can also promote 
cancer cell growth and invasion. Here we show that anticancer and cancer-
promoting RA actions in breast cancer have roots in a mechanism of mammary 
epithelial cell morphogenesis that involves both transcriptional (epigenetic) and 
non-transcriptional RARa (RARA) functions. We found that the mammary epithelial 
cell-context specific degree of functionality of the RARA transcriptional (epigenetic) 
component of this mechanism, by tuning the effects of the non-transcriptional RARA 
component, determines different cell fate decisions during mammary morphogenesis. 
Indeed, factors that hamper the RARA epigenetic function make physiological RA 
drive aberrant morphogenesis via non-transcriptional RARA, thus leading to cell 
transformation. Remarkably, also the cell context-specific degree of functionality 
of the RARA epigenetic component retained by breast cancer cells is critical to 
determine cell fate decisions in response to physiological as well as supraphysiological 
RA variation. Overall this study supports the proof of principle that the epigenetic 
functional plasticity of the mammary epithelial cell RARA mechanism, which is 
essential for normal morphogenetic processes, is necessary to deter breast cancer 
onset/progression consequent to the insidious action of physiological RA.
INTRODUCTION
Epigenetic regulation of transcription plays a 
significant role in development by regulating major 
developmental processes, such as X-inactivation, 
imprinting, and spatiotemporal activation of homeobox 
genes [1]. In the course of animal evolution, development 
became dependent also on an environmental factor from 
plant and animal sources, all-trans retinoic acid (hereafter 
RA), that epigenetically regulates transcription by 
binding nuclear RA receptors (RARs) [2–5]. In response 
to RA variation RARs, as heterodimers with rexinoid 
receptors (RXRs) [6], by recruiting chromatin coactivator 
or corepressor regulatory complexes and chromatin 
modifying enzymes, finely regulate the chromatin at genes 
characterized mostly, but not exclusively, by specific 
RA responsive elements (RAREs) [7, 8], thus creating 
a connection between this environmental signal and the 
genome [9, 10].
Fine-tuning the balance between active and repressed 
chromatin is one of the most crucial tasks of cell fate 
decision during development. Genome-wide transcriptional 
regulation in response to precise spatiotemporal variation 
of physiological RA – which, as a morphogen, determines 
cell fate in a concentration-dependent manner – has been 
considered an essential underlying molecular mechanism 
impacting several facets of development: body plan, 
organogenesis, morphogenesis, differentiation and tissue 
homeostasis [2, 4, 11–13]. Indeed too much or too little 
RA dramatically hinders developmental processes and 
produces teratogenic effects [14]. Since generation of 
precise RA level variation is of essence for determining 
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cell fate decisions during normal development, animal 
cells evolved mechanisms to regulate transcriptionally also 
genes controlling the metabolism of RA and its precursors, 
including Retinol/Vitamin A [15]. Interestingly, animal 
evolutionary studies identified molecular vestiges of a two-
module RA mechanism encompassing a ‘RA metabolic 
module’ integrated with a ‘RA signaling module’ regulating 
gene expression [16].
In specific developmental contexts, the RA-RAR 
mechanism is connected with different upstream and 
downstream nuclear receptors. For example, in epithelial 
cells of the mammary gland, nuclear RARα (RARA), 
on one hand, is directly transcriptionally regulated via 
estrogen receptor α (ERA) [17] and, on the other hand, 
directly regulates the transcription of downstream RARs, 
including the tumor suppressor RARβ2 (RARB2) [18], 
thus establishing developmental-specific transcriptional 
cascades epigenetically regulated by hormone and RA 
signals. Moreover, RA controls other transcriptional 
signaling pathways via different nuclear receptors, such as 
peroxisome proliferator-activated receptor β/δ (PPARD) [19, 
20] and chicken ovalbumin upstream promoter transcription 
factor 2 (COUP-TFII) [21]. There is compelling evidence 
that RA can also regulate in a non-transcriptional fashion 
different kinases either by direct interaction, as in the case 
of protein kinase C alpha (PKCA) [22, 23], or via RARA, 
as in the case of phosphatidyl inositide 3 kinase (PI3K) [24], 
thus establishing a cross-talk between different RA signaling 
pathways [25, 26].
This complexity, which possibly evolved to suit 
specific developmental and physiological needs during 
animal evolution, emerges also in cancer. Normal cells, when 
turn malignant, grow and invade at distant sites unchecked 
by growth-inhibitory and pro-apoptotic physiological signals 
[27], including physiological RA signal. There is in vivo 
mechanistic evidence that preventing physiological RA 
from activating wild type RARA transcriptional function in 
the mammary gland induces typical breast cancer features, 
such as aberrant ductal morphology and excessive cell 
proliferation [28]. Similarly, in vitro studies, including 
ours, indicate that functional inhibition of wild type RARA 
transcriptional activity in mammary epithelial cells changes 
physiological RA action from morphogenetic to cancer-
promoting [18, 29–33]. Consistently, breast cancer cells 
without RARA mutations, but with epigenetic signs of 
functional inhibition of RARA transcriptional activity, form 
tumors under in vivo physiological RA conditions [34, 35]. 
As reported in clinical trials for other cancers [36], we found 
that supraphysiological RA exerts paradoxical opposing 
actions also on breast cancer cell growth, depending on 
the level/functionality of wild type RARA among different 
breast cancer cell contexts, as well as within the same breast 
cancer cell context [34, 35, 37].
In this study, we traced both anti-cancer and cancer-
promoting actions of physiological and supraphysiological 
RA in breast cancer cells to the plasticity of a RARA 
epigenetic mechanism of normal mammary epithelial cell 
morphogenesis. Different from the two-module mechanism 
inferred from evolutionary studies [16], the mechanism 
that we show here encompasses a ‘RA metabolic module’ 
integrated not only with the ‘RARA transcriptional 
module’, which exerts a genome-wide epigenetic control 
of RARA-target genes, but also with a ‘non-transcriptional 
RARA module’, which controls PI3K kinase signaling 
pathways. All three modules are indispensable for normal 
morphogenesis of lumen-enclosing epithelial monolayers 
typical of the mammary gland tree. However, the plasticity 
of the RARA transcriptional arm, which is the epigenetic 
regulatory component of this mechanism, is critical to 
determine the different actions of physiological RA and 
consequent cell fate decisions during normal morphogenesis. 
Conversely, as shown here in a mammary epithelial cell 
context, a dysfunctional RARA transcriptional arm can 
determine: a) the physiological RA cancer-promoting action 
leading to aberrant mammary morphogenesis, which is 
a feature of breast cancer initiation, b) differential cancer-
promoting actions of physiological (endogenous) RA during 
cancer progression, and even c) paradoxical anticancer and 
cancer-promoting actions of supraphysiological (exogenous) 
RA used for cancer treatment. Overall, this study supports 
the proof of concept that RA breast cancer-promoting action 
has roots in a cell-autonomous RARA epigenetic mechanism 
of mammary morphogenesis.
RESULTS
Evidence that regulation of breast cancer cell 
growth by RA implicates, in addition to the 
RARA transcriptional function, another RARA 
function
RA, which is considered a powerful anti-cancer 
agent, can paradoxically promote cancer growth and 
invasion [36, 38, 39]. Our previous studies, aimed at 
unraveling mechanism(s) of the different RA actions in 
breast morphogenesis and tumorigenesis, pointed to the 
involvement of both an epigenetic component and different 
RA signaling pathways [18, 29, 34, 35, 37, 40]. The in vitro 
and in vivo studies reported hereafter provide the first clues 
of a cell-autonomous epigenetic mechanism that can explain 
both anticancer and cancer-promoting RA actions.
By global gene expression microarray analysis we 
found that in breast cancer cells (T47DCtrl) grown under 
‘physiological’ (‘physio’) RA culture conditions, many 
RARA-target genes are in a repressed transcriptional 
state marked by epigenetic histone modifications, but are 
transcriptionally responsive to high ‘supraphysiological’ 
(‘supra’) exogenous RA (10-6M) in the culture medium 
(Figure 1A, based on Supplementary Table S1, and 
Supplementary Figure S1). In nude mice fed a normal 
control diet, T47DCtrl cells grow as xenograft tumors, 
indicative of acquisition of resistance to physiological RA 
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Figure 1: Evidence that regulation of breast cancer cell growth by RA implicates, in addition to the RARA transcriptional 
function, another RARA function. A. Analysis of human gene expression microarrays shows that the transcription of RARA-target 
genes is repressed under ‘physiological’ (‘physio’) RA conditions, but can be reactivated by ‘supraphysiological’ (‘supra’) RA (10-6 M) in 
T47DCtrl cells. B. T47DCtrl xenograft tumors are growth-inhibited in nude mice fed a RA-enriched diet relative to a control diet (***p<0.001) 
(top, left), consistent with CYP26A1 transcript induction in both mice liver and tumors (*p<0.05, **p<0.01) (top, right). 3D T47DCtrl 
growth (assessed by EdU incorporation) is promoted by low ‘supraphysiological’ RA (10-9 M) (*p<0.05), but inhibited by high RA (10-7 
M) (*p<0.05). C. ‘Supraphysiological’ RA promotes 2D T47DCtrl cell growth (assessed by colony formation) at concentrations below the 
threshold required for induction of CYP26A1 and RARB2 transcripts (measured by qRT-PCR), but inhibits growth above this threshold 
(CYP26A1: RA 10-7M = **p<0.01, RA 10-6M = *p<0.05; RARB2: RA 10-7M = ***p<0.001, RA 10-6M = **p<0.01; growth: RA≤10-9 M 
= *p<0.05, RA≥10-7M = ***p<0.001; relative to ‘physio’ RA). D. In T47D403 cells, ‘supraphysiological’ RA does not re-activate RARA-
target gene expression as it does in T47DCtrl cells. E. The RA-enriched diet promotes T47D403 xenograft tumor growth (***p<0.001) 
(top, left). This diet induces CYP26A1 transcript in mice liver but not in xenograft tumors (**p<0.01) (top, right). Both low and high 
‘supraphysiological’ RA promote 3D T47D403 growth (*p<0.05) (bottom). F. ‘Supraphysiological’ RA induces CYP26A1 (RA 10-7M = 
*p<0.05, RA 10-6M = **p<0.01) and RARB2 (RA 10-7M = ***p<0.001, RA 10-6M = **p<0.01) significantly less relative to T47DCtrl cells. 
At all concentrations, RA promotes 2D T47D403 growth (***p<0.001, relative to ‘physio’ RA). G. The RARA agonist AM580 recapitulates 
the effects of RA on cell growth (T47DCtrl: **p<0.01 and T47D403: ***p<0.01, relative to untreated) and RARB2 transcription (T47DCtrl: 
AM580≥10-8M = **p<0.01, relative to untreated; T47D403: **p<0.01, relative to T47DCtrl). H. Stable knock down of wild type RARA in 
T47D403 cells (left) counteracts RA-induced cell growth (assessed by colony formation assay, right) (**p<0.01). Student’s t-test was used 
for in vitro studies and ANOVA for in vivo studies. RU= relative units.
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anticancer action, but are growth-inhibited in mice fed a 
RA-enriched diet (Figure 1B, top left). The transcription of 
cytochrome P450 26A1 (CYP26A1), a prototypic RARA-
target gene used as an indicator of RA level variation [41], 
is induced by a RA-enriched diet in both liver and T47DCtrl 
tumors (Figure 1B, top right). To rapidly assess the effects 
of increasing ‘supraphysiological’ RA (from 10-9M to 10-7M) 
on T47DCtrl cell growth, we grew cells in three-dimensional 
(3D) culture (Matrigel), where they form amorphous 
structures typical of breast tumorigenic cells [42]. Both in 
3D (Figure 1B, bottom) and two-dimensional (2D) (Figure 
1C) culture, T47DCtrl cell growth is promoted by RA only 
below the 10-8 M threshold level, where there is no, or 
insufficient, transcriptional activation of both CYP26A1 and 
the tumor suppressor RARB2 gene (Figure 1C).
Ectopic expression of the dominant negative 
RARA403 mutant in the T47D context (T47D403) further 
represses the already repressed transcriptional state of 
RARA-targets (Figure 1D, based on Supplementary 
Table S1, and Supplementary Figure S1). This explains 
why CYP26A1 remains transcriptionally repressed in 
T47D403 tumors, but not in the liver of mice fed the RA-
enriched diet (Figure 1E, top right), even when tumors 
grow significantly more than in mice fed a normal diet 
(Figure 1E, top left). Likewise, ‘supraphysiological’ RA, 
both below and above the 10-8 M RA threshold, promotes 
both 3D (Figure 1E, bottom) and 2D (Figure 1F) growth 
of T47D403 cells, because it cannot reactivate effectively 
the transcription of RARA-target genes (Figure 1F). 
Indeed, even at high ‘supraphysiological’ RA (>10-8M), 
both CYP26A1 and RARB2 transcripts are induced 
significantly less in T47D403 than in T47DCtrl (Figure 1F).
We excluded that the RA growth-promoting action 
is limited to either the specific RARA403 mutation or the 
T74D breast cancer cell context, because we observed 
RA induction of cell growth also when we took into 
consideration another dominant negative RARA allele 
(RARAG303E) (Figure S2A) and another breast cancer 
cell context (MCF7) (Supplementary Figure S3).
We did also exclude that the mediator of 
‘supraphysiological’ RA cancer-promoting action in 
breast cancer cells with inhibition of RARA transcriptional 
function is PPARD. As shown here by both genetic and 
pharmacological approaches, we discounted a role of 
PPARD in the T47D breast cancer cell context with 
maximal inhibition of RARA transcriptional function 
(Supplementary Figure S4A-D). Interestingly, in the 
course of these experiments, we instead found that RARA-
specific agonists (shown here AM580) recapitulate the 
cancer-promoting and transcriptional effects of RA 
(Supplementary Figure S4E), suggesting that, in addition 
to RARA transcriptional function, another RARA function 
is involved in the control of cancer cell growth. Indeed, in 
T47D contexts with either wild type RARA (T47DCtrl) or 
dominant negative mutant RARA alleles (T47DG303E and 
T47D403), the dose-dependent effects of AM580 variation 
(Figure 1G and Supplementary Supplementary Figure 
S2B) mirrors the dose-dependent effects of RA variation 
on both cell growth and RARB2 transcription (Figure 1C, 
bottom, Figure 1F, bottom, and Supplementary Figure 
S2A, bottom). Moreover, wild type RARA knock down in 
the T47D403 context with a RARA-targeting short hairpin 
RNA (shRNA) (Figure 1H, left) significantly counteracts 
cancer cell growth induced by high ‘supraphysiological’ 
RA (10-6 M) (Figure 1H, right).
These findings prompted us to search for further 
evidence of the “other” putative RARA function involved 
in the regulation of T47D breast cancer cell growth by RA.
Evidence of combinatorial effects of both RA-
RARA-mediated transcriptional activation and 
RA-RARA-mediated PI3K activation on breast 
cancer cell growth
According to literature, in cancer cells RA can 
activate PI3K kinase by enhancing RARA physical 
interaction with the PI3K catalytic subunit (p110) [24]. 
After identifying by immunoprecipitation a protein 
complex comprising wild type RARA, the regulatory 
PI3K subunit (p85α), and the catalytic PI3K mutant 
subunit (p110α) (Figure S5A, left) in the T47D cell 
context, we found by proximity ligation assay (PLA) that 
both low RA (10-9M) and the RARA agonist AM580 (10-9 
M) did enhance RARA-p110α interaction (Figure S5A, 
right). Next, we found that after the first hour of a 72 hour-
treatment of T47DCtrl cells with increasing exogenous RA 
(from 10-10M to 10-6M), the extent of activation of both 
RARA transcription (RARB2 transcript level, green) 
and PI3K (phosphorylation of the PI3K effector AKT, 
red) correlates with the growth outcome (assessed by 
colony formation after the 72 hour RA treatment, blue) 
(Figure 2A, left). As shown hereafter, the relationship 
between cell growth and activation of the two RARA 
functions in response to exogenous RA variation seems 
to be influenced by the cell context-specific degree of 
inhibition of RARA transcriptional function: mild in 
T47DCtrl, severe in T47DG303E, and extremely severe in 
T47D403 (Figure 2A). Under ‘physiological’ RA culture 
conditions (that is without addition of exogenous RA), 
T47DCtrl, T47DG303E, and T47D403 cells display only a 
basal P-AKT level (Figure 2A). In contrast, exogenous, 
‘supraphysiological’ RA variation induces a similar 
increase of AKT phosphorylation (P-AKT) in the 
three cell contexts, but differentially induces RARB2 
transcript level (Figure 2A). Regression analysis shows 
that, in response to increasing exogenous RA, the growth 
outcome of T47DCtrl, T47DG303E, and T47D403 reflects 
the combined effect of cell context-specific activation 
of both transcriptional and non-transcriptional RARA 
functions (Figure 2A). This interpretation is supported 
by evidence of a significantly decreased RA-induced 
T47D403 cell growth – in correlation with a reduced 
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P-AKT level – after stable wild type RARA knock down 
in T47D403 (Figure 2B). Consistently, treatment with 
either the RARA antagonist ER50891 (Figure 2C, top) 
or the PI3K inhibitor LY294002 (Figure 2C, bottom) 
significantly counteracts T47D403 growth induced by 
either RA or the RARA agonist AM580. It is noteworthy 
to mention that also Retinol/Vitamin A (ROH), a 
dietary RA precursor, which activates PI3K signaling 
(but not RARA transcriptional signaling) in T47D403 
cells, promotes cell growth both in vitro and in vivo 
(Supplementary Figure S6).
By confocal microscopy of 3D mature acini formed 
by T47DCtrl and T47D403 cells stably transfected with 
a RARE-GFP reporter, we could infer the combined 
biological effects of both transcriptional (GFP, green) 
and non-transcriptional (P-AKT, red) RARA functions at 
both ‘physiological’ and increasing ‘supraphysiological’ 
RA culture conditions. Only P-AKT is detectable in 3D 
mature T47DCtrl-GFP acini developed either in the absence 
or presence of low exogenous RA (10-9M) (Figure 2D, 
left and middle columns), while both GFP and P-AKT are 
detectable in T47DCtrl-GFP growth-inhibited acini developed 
Figure 2: Evidence of combinatorial effects of both RA-RARA-mediated transcriptional activation and RA-RARA-
mediated PI3K activation on breast cancer cell growth. A. In the T47D context, depending on the degree of functionality of 
RARA transcriptional activity (T47DCtrl > T47DG303E > T47D403), the differential growth (blue dotted line) induced by increasing exogenous 
RA reflects the combined effects of RARA transcriptional activation (assessed by RARB2 qRT-PCR, green columns) and RARA-PI3K 
activation (assessed by P-AKT quantitative Western Blot, red columns). In all clones RA concentration significantly correlates with P-AKT 
level (r=0.945, 0.91-0.97, 95% CI) and RARB2 expression (r=0.62, 0.45-0.75, 95% CI). B. Stable knock down of wild type RARA in 
T47D403 cells counteracts both PI3K activation and growth promotion induced by increasing exogenous RA. C. Treatment with either the 
RARA antagonist ER50891 (ER) (top) or the PI3K inhibitor LY294002 (LY) (bottom) counteracts T47D403 growth induced by both RA 
and the RARA agonist AM580 (AM) (*p<0.05, **p<0.01, ***p<0.001). D. ‘Supraphysiological’ RA inhibits T47DCtrl 3D growth only at 
concentrations above the threshold that can induce, in addition to RARA-PI3K signaling (assessed by P-AKT), also RARA transcriptional 
signaling (assessed by RARE-GFP). E. In contrast, ‘supraphysiological’ RA, at all concentrations, only promotes T47D403 3D growth, 
because it sustains RARA-PI3K signaling, but does not activate RARA transcriptional signaling. Significance calculated by standard linear 
regression (A) or Student’s t-test (C).
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in the presence of high exogenous RA (10-7M) (Figure 2D, 
right column). Conversely, T47D403-GFP cells developed 
into 3D acini expressing only P-AKT, even at high 
‘supraphysiological’ RA culture conditions (Figure 2E).
Based on these findings, breast cancer cell fate 
decisions seem to depend on how the biological effects 
of RARA-mediated transcriptional regulation of direct 
target genes keep in check the cancer-promoting effects of 
RARA-mediated activation of PI3K effectors in response 
to RA variation. Thus, we set out to substantiate our 
hypothesis with additional experiments shown hereafter.
RA promotes breast cancer cell invasion 
via RARA-PI3K when it cannot reactivate 
transcriptionally silent tumor suppressor RARA-
target genes: A proof of concept
In vivo experiments show that a RA-enriched diet 
promotes not only tumor growth (Figure 3A, left), but also 
invasion of T47D403 cells expressing red fluorescent protein 
(RFP) (Figure 3A, right). In vitro, high ‘supraphysiological’ 
RA (10-6 M) significantly promotes T47D403 invasion 
(Figure 3B) in correlation with epigenetic transcriptional 
repression of tumor suppressor RARA-targets, including the 
transforming growth factor β (TGFB) receptor 2 (TGFBR2) 
(Figure 1D and Supplementary Figure S1). Indeed, TGFBR2 
transcription remains epigenetically repressed both in the 
T47DCtrl and T47D403 cell contexts at no/low exogenous 
RA, but it is still amenable of being reactivated by high 
exogenous RA (>10-8M) in T47DCtrl cells (Figure 3C), 
confirming that the epigenetic TGFBR2 transcriptional 
repression in the T47D403 cell context is more severe than in 
T47DCtrl (Supplementary Figure S1). In response to high RA, 
T47DCtrl cells – but not T47D403 cells – transduce the signal 
of both endogenous TGFB (detected by western blot, Figure 
3D, left) and exogenous TGFB (2 ng/ml) (Figure 3D, right).
To mechanistically test whether the activation 
of TGFB-TGFBR2 signaling pathway contributes to 
deter RA pro-invasive action, we functionally inhibited 
TGFBR2 in the T47DCtrl cell context by stably expressing 
a TGFBR2 dominant negative mutant (TR2DN) that 
cannot transduce TGFB signal (scheme in Figure 3E, 
left) [43]. High RA (10-6M), by inducing TGFB signaling 
significantly less in T47DTR2DN than in T47DCtrl (Figure 
3E, middle), promotes T47DTR2DN cell invasion (Figure 
3E, right). Conversely, ectopic expression of TGFBR2 in 
the T47D403 cell context, by re-enabling TGFB signaling 
pathway (Figure 3F, left), counteracts RA-induced cell 
invasion (Figure 3F, right). Finally, we found that the PI3K 
inhibitor LY294002 counteracts T47D403 cell invasion 
induced by either RA (10-6M), or the RARA-specific 
agonist AM580 (50 nM) (Figure 3G).
These findings support the proof of concept that RA 
exerts a breast cancer-promoting action whenever, due to 
epigenetic repression, RARA-transcriptionally-regulated 
tumor suppressor signaling pathways (e.g. TGFB-
TGFBR2) fail to counteract the effects of RARA-PI3K/
AKT signaling pathway.
Both cell context-specific physiological 
endogenous RA synthesis and transcriptional 
functionality of RARA differentially determine 
breast cancer cell fate
As shown before, the breast cancer cell context-
specific RARA transcriptional functionality seems to be 
critical for determining cell fate decisions in response to 
‘supraphysiological’ RA variation. By the same token, due 
to heterogeneous expression of aldehyde dehydrogenase 
(ALDH), the enzyme involved in physiological RA 
synthesis [44], within a breast cancer cell population [45], 
we set out to test if breast cancer cell fate decisions may 
depend on both the cell context-specific transcriptional 
functionality of RARA and physiological endogenous RA 
synthesis variation.
First, by labeling T47DCtrl cells with PKH26, a 
fluorescent cell linker that – by being more and more 
diluted after each cell division – can discriminate between 
slow- and fast-proliferating cells (Figure 4A, bottom), we 
found that the fast-proliferating cell subset (low PKH26, 
green frame) contains ~50% more cells with high ALDH 
activity (ALDHhigh cells, detected by Aldefluor staining) and 
expresses ~45% more P-AKT (assessed by immunostaining) 
relative to the slow-proliferating cell subset (high PKH26, 
blue frame) (Figure 4A, top). Inhibition of either ALDH-
mediated RA synthesis with DEAB (Figure 4B, left), or 
PI3K activity with LY294002 (Figure 4B, right), results 
in a decrease of both P-AKT level and cell proliferation. 
Similarly, both DEAB and LY294002 severely hamper 
3D T47DCtrl acinar growth in Matrigel (Figure 4C). Thus, 
ALDH-mediated physiological RA synthesis contributes to 
promote T47DCtrl cell proliferation by activating the RARA-
mediated PI3K/AKT signaling pathway.
Second, we found that the cell context-specific degree 
of inhibition of RARA transcriptional function affects 
the size of the subset of cells with higher ALDH activity 
because, by Aldefluor cytofluorimetric analysis, we detected 
more ALDHhigh cells in T47D403 vs. T47DCtrl cells (27.6% vs. 
17.9%) (Figure 4D). Relative to T47DCtrl, T47D403 also show 
enrichment of ALDHhigh/CD44high/CD24low cells (Figure 
4E), which according to literature should have increased 
tumorigenic and metastatic potential [46]. These molecular 
features are congruent with acquisition by T47D403 cells 
of cytoskeleton-related molecular changes known to favor 
cell migration/invasion (scheme in Figure 4F, left, based 
on global gene/protein expression analyses, not shown), 
defective actin stress fiber formation (Figure 4F, middle), 
and increased cell migration (Figure 4F, right). Further, 3D 
T47D403 mature acini, relative to 3D T47DCtrl acini, display 
more proliferating CD44high cells (Figure 4G).
These findings indicate that, within a breast cancer 
cell population, based on the transcriptional functionality 
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of RARA, a higher endogenous RA synthesis favors 
the proliferation of cells with pro-invasive features via 
RARA-regulated PI3K/AKT signaling pathway.
Overall, our studies using breast cancer cells let us 
envision that the different RA biological actions had to do 
with a cell-autonomous mechanism capable of determining 
cell fate decisions based on the combinatorial effects of both 
transcriptional and non-transcriptional RARA functions in 
response to RA variation. To prove the existence of this 
mechanism, we needed a developmental model that let us 
harness precise physiological RA variation to assess the 
combinatorial effects of spatiotemporal activation of the 
Figure 3: RA promotes breast cancer cell invasion via RARA-PI3K when it cannot reactivate transcriptionally silent 
tumor suppressor RARA-target genes: A proof of concept. A. A RA-enriched diet promotes not only the growth of RFP-positive 
T47D403 xenograft tumors (left), but also the formation of lung metastases (right) (**p<0.01). B. High ‘supraphysiological’ RA promotes 
T47D403 invasion in the Boyden chamber assay (Giemsa-stained invading cells in representative fields are shown on the right) (**p<0.01). C. 
‘Supraphysiological’ RA induces TGFBR2 transcript significantly less in T47D403 than in T47DCtrl (RA≥10-7M = *p<0.05) D. Consistently, 
T47D403 cells cannot transduce the signal of both endogenous TGFB (detected by western blot in D, left) and exogenous TGFB, alone 
or in combination with exogenous RA (shown by CAGA-luc assay in D, right) (*p<0.05, **p<0.01). E. Stable expression of a TGFBR2 
dominant negative (DN) mutant (left) in T47DCtrl cells (T47DTR2DN), by inhibiting TGFB signaling (assessed by CAGA-luc assay, middle), 
makes cells invade more in response to exogenous RA (right) (*p<0.05, **p<0.01). F. Conversely, stable expression of TGFBR2 in T47D403 
cells, by re-enabling TGFB signaling (CAGA-luc assay, left), counteracts RA-induced cell invasion (right) (*p<0.05, **p<0.01). G. RA-
induced T47D403 cell invasion implicates activation of RARA-PI3K signaling, because PI3K inhibition by LY294002 (LY) significantly 
counteracts cell invasion induced by either exogenous RA or the RARA agonist AM580 (**p<0.01). Student’s t-test was used for in vitro 
studies and ANOVA for in vivo studies.
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two RARA functions. The 3D morphogenesis model of 
non-tumorigenic human mammary epithelial HME1 cells, 
which express wild type RARA, wild type PI3K subunits, 
and ADLH1A1 (see Supplementary Materials and Methods), 
seemed to us a suitable model to test our hypothesis.
Tracing the different biological actions of 
physiological RA to a RARA mechanism of 
mammary epithelial cell fate
When seeded in 3D culture on Matrigel, HME1 
cells develop into lumen-enclosing monolayers typical of 
normal breast ducts and lobules in about 12 days (Figure 
5A, top). We first set out to test if precise endogenous 
RA level generated from RA precursors in the 3D culture 
microenvironment, as well as the integrity of both 
transcriptional and non-transcriptional RARA functions, 
were required for normal 3D HME1 morphogenesis. As 
shown here, perturbation of physiological RA level by 
either inhibiting ALDH-mediated RA synthesis with DEAB, 
or adding ‘supraphysiological’ exogenous RA (10-9 M), 
hinders 3D HME1 development (Figure 5A, bottom). We 
know from our previous studies that inhibition of RARA 
transcriptional function by genetic factors in HME1 cells 
Figure 4: Both cell context-specific physiological endogenous RA synthesis and transcriptional functionality of RARA 
differentially determine breast cancer cell fate. A. Cytofluorimetric analysis of PKH26-labeled T47DCtrl cells shows that the fast-
proliferating cell subset (green frame) contains more cells with high ALDH activity (ALDHhigh cells, detected by Aldefluor staining) and 
expresses more P-AKT relative to the slow-proliferating cell subset (blue frame). B. Inhibition of either ALDH-mediated RA synthesis 
with DEAB (left), or PI3K activity with LY294002 (right) results in a decrease of both P-AKT level (top) and cell proliferation (bottom) 
(**p<0.01, ***p<0.001). C. Treatment with either DEAB or LY294002 inhibits T47DCtrl proliferation also in 3D culture. D-E. Increased 
inhibition of RARA transcriptional function in T47D403 cells leads to expansion of both ALDHhigh (D) and ALDHhigh/CD44high/CD24low (E) 
subpopulations relative to T47DCtrl. F. Global gene/protein expression analyses highlight pro-invasive molecular changes in T47D403 vs. 
T47DCtrl (left). Consistently, T47D403 cells show defective phalloidin-stained actin stress fibers (middle) and increased cell migration in the 
wound healing assay (right) (*p<0.05). G. Confocal analysis shows that 3D T47D403 acini have a higher proportion of CD44high cells relative 
to 3D T47DCtrl acini (**p<0.01), and that the T47D403 CD44high cell subpopulation contains more proliferating (EdU-positive) cells than the 
CD44low cell subpopulation (**p<0.01). Significance calculated by Student’s t-test.
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[18, 29, 31] results into morphologically aberrant 3D acinar 
structures (see a representative 3D acinus formed by HME1 
expressing the RARA403 dominant negative mutant allele in 
Figure 5B, left [18]). We instead found, as shown here, that 
RA promotes RARA-PI3K (p110α) interaction in the HME1 
cell context (Supplementary Figure S5B), and that inhibition 
of PI3K activity hinders 3D acinar development (Figure 5B, 
right). Overall, these findings let us envision a HME1 cell 
RA-RARA mechanism encompassing a ‘RA metabolic 
module’ that generates RA variation and is integrated with 
Figure 5: Tracing the different biological actions of physiological RA to a RARA mechanism of mammary epithelial 
cell fate. A-B. HME1Ctrl human mammary epithelial cells 3D morphogenesis (A, top) requires precise ‘physiological’ RA variation as well 
as transcriptional and non-transcriptional RARA functions, because 3D morphogenesis is hampered by both perturbation of ‘physiological’ 
RA level (e.g. ALDH inhibition by DEAB or addition of exogenous ‘supraphysiological’ RA) (A, bottom) and inhibition of either RARA 
transcriptional function (B, left) or RARA-PI3K signaling pathway (B, right). C. Hypothetical RA-RARA mechanism of mammary 
epithelial cell fate encompassing a RA metabolic module, a transcriptional RARA module exerting an epigenomic control of RARA-
target genes, and a non-transcriptional RARA module controlling PI3K activity. D. HME1Ctrl cells stably transfected with RARE-GFP 
(HME1Ctrl-GFP) show differential spatiotemporal activation of RARA transcriptional signaling (GFP) and RARA-PI3K signaling (P-AKT) 
by ‘physiological’ RA at different stages of 3D morphogenesis. E-F. ‘Physiological’ RA fails to induce transcriptional RARA signaling (no 
GFP), but keeps sustaining RARA-PI3K signaling (P-AKT) during aberrant morphogenesis of both HME1403-GFP, with inhibition of RARA 
transcriptional function by RARA403 (E), and T47DCtrl-GFP, with inhibition of RARA transcriptional function by unknown factors (F).
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both a ‘transcriptional RARA module’, capable of exerting 
an epigenomic control of RARA-target genes, and a ‘non-
transcriptional RARA module’, capable of controlling PI3K 
activity (Figure 5C).
To assess if physiological RA variation generated 
during 3D morphogenesis indeed induces the concerted 
dynamic activation of the two RARA functions, we imaged 
HME1Ctrl-GFP cells, stably transfected with a RARE-GFP 
reporter, by confocal microscopy. With this approach, we 
detected activation of PI3K (assessed as P-AKT, red) at 
all stages of 3D morphogenesis, and activation of RARA 
transcriptional function (assessed as GFP, green) only at 
intermediate stages, in a subset of cells likely destined to clear 
the lumen (Figure 5D). These observations let us infer that 
RARA transcriptional function, when inhibited, enables the 
pro-proliferative and pro-survival actions of ‘physiological’ 
RA and, when activated, enables RA growth-inhibitory 
and pro-apoptotic actions. In the latter case, the biological 
effects of the RARA transcriptional function override the 
biological effects of the non-transcriptional RARA function. 
Conversely, at all stages during aberrant 3D morphogenesis 
of HME1403-GFP cells, with an inhibited RARA transcriptional 
function, we detected only signs of PI3K activity (assessed as 
P-AKT) (Figure 5E). Similarly, at all stages during aberrant 
3D development of T47DCtrl-GFP cells, we detected only signs 
of PI3K activity and RARA transcriptional inactivity (Figure 
5F). The latter is likely due to genetic alterations other than 
RARA mutations, because as mentioned before, T47D cells 
express wild type RARA. We tested and found that, in the 
HME1 cells context, genetic alterations that do not affect the 
RARA structural integrity, but negatively interfere with just 
the RARA transcriptional function (e.g. mutations of the RA 
transport protein CRABP2 [29, 47] and ectopic expression of 
MYC [48]), let physiological RA activate only the RARA-
PI3K/AKT signaling pathway (Supplementary Figure S7). 
Thus, HME1 cell fate decisions during 3D morphogenesis 
seem to be determined by how effectively the transcriptional 
component of the RARA mechanism keeps in check the 
non-transcriptional RARA component in response to 
‘physiological’ RA variation.
Next, we asked whether the extent of physiological 
RA signal variation influences cellular decisions at different 
3D developmental stages of HME1Ctrl and HME1403 cells 
by determining combinatorial effects of different signaling 
pathways. We got a glimpse on the dynamics of signaling 
pathways activated by physiological RA by bioinformatics 
analysis of the transcriptome (RNA-seq.) profile of both 
HME1Ctrl and HME1403 at different stages of morphogenesis 
(Supplementary Figure S8, based on Supplementary Table 
S2). Interestingly, bioinformatics analysis of HME1Ctrl 
3D acini at 1, 3, 6, and 9 days of morphogenesis relative 
to 2D HME1Ctrl cells with a strategy based on Monocle 
[49] let us identify nine gene clusters, including subsets of 
direct RARA-target genes, that share a similar expression 
trend during 3D morphogenesis (blue lines) (Figure 6A, 
and Supplementary Table S3). Some of these clusters are 
associated with morphogenetic signaling pathways known 
to be either directly transcriptionally regulated by RARA 
(see the pro-apoptotic SMPD3-ceramide and the TGFB-
TGFBR2 signaling pathways of cluster 6, red arrows), or 
non-transcriptionally regulated by RARA (see PI3K/AKT 
signaling pathway of cluster 1, blue arrows) (Figure 6B). 
Moreover, comparison between HME1403 and HME1Ctrl 
at corresponding stages of 3D maturation, let us highlight 
significant (p<0.05) deregulation of gene expression at 
stages either preceding lumenogenesis (day 6), or after 
completion of lumen formation (day 9) (Figure 6A, orange 
lines). It is noteworthy that bioinformatics analysis of the 
transcriptome of HME1403 vs. HME1Ctrl cells in 2D culture 
did also reveal that mammary epithelial cells harbor a 
‘built-in’ potential to undergo either normal or aberrant 3D 
morphogenesis even before they are seeded in 3D culture 
(Supplementary Figure S9).
Overall, confocal imaging analysis and 
bioinformatics analysis did provide complementary 
evidence supporting the conclusion that HME1 mammary 
epithelial cell fate decisions reflect the combinatorial 
biological effects induced by the spatiotemporal activation 
of both transcriptional (epigenetic) and non-transcriptional 
RARA functions by physiological RA. Clearly, the cell 
context-specific RARA transcriptional epigenetic plasticity 
that determines morphogenetic processes is critical to 
deter cell transformation.
DISCUSSION
All-trans RA, the bioactive derivative of Retinol 
(Vitamin A), a powerful physiological anticancer agent, 
can paradoxically foster cancer initiation and progression. 
Resistance to physiological RA growth-inhibitory action 
was traced for the first time to RARA transcriptional 
inactivity due to leukemia-associated dominant negative 
RARA mutations, which determines genome-wide 
epigenetic deregulation of RARA-target genes [50, 51]. 
With the exception of leukemia, according to The Cancer 
Genome Atlas, most cancers, including breast cancer, carry 
many genetic alterations but not RARA mutations, even if 
they all display resistance to physiological RA anticancer 
action. Upon stable inhibition of RARA transcriptional 
function by ectopic expression of dominant negative 
RARA mutant alleles in the mouse mammary gland, 
physiological RA was shown to sustain aberrant branching 
morphogenesis and excessive cell proliferation via a cell-
autonomous mechanism [28]. Similarly, both mouse and 
human non-tumorigenic mammary epithelial cells, upon 
functional inhibition of RARA transcriptional activity, 
develop in vitro resistance to the morphogenetic, growth-
inhibitory actions of physiological RA that, nevertheless, 
contributes to promote cell survival/proliferation [18, 33]. 
Further, as emerged from clinical cancer chemoprevention 
trials [36, 38, 39], cancer cells can paradoxically grow 
and invade more in response to low supraphysiological 
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RA treatment, implying that there must be a mechanism 
that mediates the cancer-promoting action of both 
physiological and even supraphysiological RA.
In this study we provide evidence that both the anti-
cancer and the cancer-promoting action of physiological 
RA in breast cancer have roots in a developmental RARA 
epigenetic mechanism of mammary epithelial cell fate. 
First, by harnessing the response to supraphysiological 
(exogenous) RA variation of breast cancer cells with a 
different degree of transcriptional RARA functionality, we 
Figure 6: Bioinformatics analysis sheds light on the dynamics of RARA-regulated signaling pathways during 
3D mammary epithelial morphogenesis. A. Comparison of the RNA-seq profile of HME1Ctrl acini at 1, 3, 6, and 9 days of 3D 
morphogenesis relative to cells grown in 2D culture identifies clusters of genes (including RARA-targets, see red portion of the pie charts) 
with similar expression trend during 3D morphogenesis (blue lines). The expression of many of these genes is significantly (p<0.05) 
different at specific stages (dotted squares) of 3D HME1403 aberrant morphogenesis (orange lines). B. According to Metacore pathway 
enrichment analysis, these gene clusters are significantly (p<0.05) associated with specific signaling pathways (left) involved in diverse 
cellular functions (pie charts on the right), including pathways modulated by RARA transcriptional (red arrows) and non-transcriptional 
(blue arrows) functions. Statistical analysis as reported in Supplementary Materials and Methods.
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found that RA coordinates, in a dose-dependent fashion, 
both transcriptional RARA signaling a non-transcriptional 
RARA-PI3K signaling. At each RA concentration, the 
cancer cell growth outcome seems to reflect the combined 
effects of both the ‘absence’ of epigenetic transcriptional 
activation of RARA-targets (e.g. tumor suppressor 
functions like RARB2 and TGFBR2) and activation of 
PI3K kinase effectors (e.g. P-AKT).
Second, by using a panel of isogenic HME1 
mammary epithelial cells, we found that also physiological 
(endogenous) RA variation, generated in the course of 3D 
morphogenesis of lumen-enclosing mammary epithelial cell 
monolayers, induces the concerted spatiotemporal activation 
of both a transcriptional signaling and a PI3K signaling 
via distinct RARA functions. Both precise endogenous 
physiological RA variation and the integrity of the two 
(transcriptional and non-transcriptional) RARA functions 
are indispensable to accomplish the mammary epithelial 
morphogenetic processes. We also found evidence that the 
functional plasticity of the RARA transcriptional (epigenetic) 
component of this mechanism critically determines 
mammary epithelial cell fate decisions by keeping in check 
the effects of RARA-regulated PI3K signaling pathways in 
the right space and at the right time.
By confocal imaging, we could assess that inhibition 
of RARA transcriptional activity by factors that selectively 
hamper RARA transcriptional function in mammary 
epithelial cells, not only impedes the growth-inhibitory/
pro-apoptotic action of physiological RA, but also gives 
the “go ahead” to physiological RA growth-promoting 
action, leading to malignant cell transformation. Moreover, 
bioinformatics RNA-seq analysis of the transcriptional 
dynamics at different stages of 3D morphogenesis of 
non-tumorigenic mammary epithelial cells shows that 
physiological RA dynamically modulates gene clusters 
associated with signaling pathways under the functional 
control of both transcriptional and non-transcriptional 
RARA. When RARA transcriptional activity is 
functionally inhibited, physiological RA activation of 
growth-promoting signaling pathways, like PI3K/AKT, is 
no longer counteracted by transcriptional RARA activation 
of tumor suppressor signaling pathways like the TGFB-
TGFBR2 signaling pathway.
Development of strategies suitable to assess the 
spatiotemporal dynamics of epigenetic events at single 
cell resolution [52–54], as well as transcriptional/non-
transcriptional RA-RARA-regulated signaling networks 
[55] in mammary epithelial cells, might help us deepen our 
understanding of the workings of the RARA epigenetic 
mechanism of mammary epithelial cell fate that, when 
goes awry, drives breast tumorigenesis.
The HME1 RARA mechanism of mammary epithelial 
cell fate has features of a proposed mechanism of normal 
mammary branching morphogenesis. HME1 cells, which 
are ER+, RARA+, and ALDH1A1+, are capable of forming 
lumen-enclosing monolayers like mammary epithelial cells 
found at the branching points of small ducts of the normal 
human breast epithelium [56]. A non-transcriptional RARA 
function seems to be involved in excessive mammary ductal 
branching morphogenesis in female mice with inhibition 
of RARA transcriptional function by a dominant negative 
RARA mutant under the murine mammary tumor virus 
(MMTV) promoter [28]. Moreover, consistent with evidence 
that in the HME1 cell context PI3K is indispensable for 3D 
acinar development, targeted homozygous ablation of the 
PI3K catalytic subunit P110α in transgenic mice severely 
impairs mammary gland development [57]. In contrast, 
constitutive activation of PI3K by forced recruitment of 
P110α to the membrane leads to increased mammary ductal 
branching and proliferation [58]. PI3K would integrate both 
mechanical and biochemical signaling of branch initiation 
and elongation in cultured mouse epithelial cells via its 
effectors AKT and RAC1 [59]. The mechanism and biology 
of RA regulation of mammary epithelial cell fate can let us 
improve detection, prevention, and treatment of early breast 
cancer.
Factors that negatively affect the RARA transcriptional 
function are expected to predispose mammary epithelial 
cells to physiological RA cancer-promoting effects. In 
breast cancer cells it is not always possible to pinpoint “the” 
factor(s) that, by inhibiting RARA transcriptional function, 
make RA exert a cancer-promoting action. Since breast 
cancer is a disease related to aging [60], not only mutations, 
but also deterioration of breast tissue per se might be a factor 
capable of negatively affecting the epigenome of breast 
epithelial cells by weakening the transcriptional functionality 
of RARA. As shown in this study, in the T47D breast cancer 
cell context, epigenetic effects due to increased inhibition 
of RARA transcriptional function result in the expansion 
of the pool of cells with high RA synthesis (ALDHhigh 
cells), including a subset of ALDHhigh/CD24low/CD44high 
cells, with increased stemness, pro-proliferative, and pro-
invasive properties [45, 46]. Thus, the breast cancer cell 
context-specific transcriptional functionality of the RARA 
mechanism, not only differentially affects the epigenetic 
state of RARA-target genes, but also determines cancer-
promoting effects of physiological RA synthesis due to the 
level of ALDH activity.
Methods to detect early signs of physiological 
RA cancer-promoting action in breast tissue could let 
us identify, and consequently target, insidious effects of 
physiological RA, thus halting or delaying breast cancer 
progression. Molecular signs of a dysfunctional RARA 
mechanism have been detected in breast cancer tissue. 
DNA hypermethylation of transcriptionally repressed 
RARA-target genes, which is interpreted as functional 
inhibition of RARA transcriptional activity [40, 61, 62], 
or AKT phosphorylation (P-AKT), which is interpreted 
as aberrant activation of PI3K kinase [63], were found in 
early stages breast cancer, even before evidence of breast 
cancer in mammograms [61].
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As shown here by bioinformatics RNA-seq. 
analysis, HME1 mammary epithelial cells have a ‘built-
in’ potential to develop into morphologically normal or 
aberrant 3D structures in the presence of ‘physiological’ 
RA based on the functional transcriptional status of RARA. 
Recently, we reported that the protein profiles of HME1 
cells that, due to different mutations, are resistant to the 
morphogenetic (growth-inhibitory/pro-apoptotic) action of 
physiological RA, differ from normal cells in 2D culture, 
i.e. before they reveal an aberrant morphology once they 
develop in 3D culture [31]. One of these protein changes 
is overexpression of Annexin A8 (ANXA8), a member 
of the annexin superfamily of membrane- and calcium-
binding proteins. Ectopic expression of ANXA8 in the 
HME1 cell context is sufficient to make cells resistant 
to physiological RA, with consequent development into 
3D amorphous structures resembling ductal carcinoma 
in situ (DCIS). Remarkably, being ANXA8 significantly 
overexpressed in DCIS versus normal tissue [31], it could 
be a valuable biomarker to infer ongoing physiological 
RA cancer-promoting action in breast tissue samples 
before breast cancer onset. When signs of physiological 
RA are detected in breast epithelial cells, epigenetic 
drugs capable of reawakening RARA-transcriptionally-
regulated tumor suppressor activities, in combination 
with drugs weakening the effect of RA activation of PI3K 
tumorigenic signaling pathways, could be used to delay 
breast cancer progression by physiological RA.
In summary, the cell context-specific plasticity of the 
RARA epigenetic mechanism of mammary epithelial cell 
fate decisions, which is critical to determine different actions 
of both physiological and supraphysiological RA (see 
scheme Figure 7), can be harnessed to improve strategies 
for breast cancer detection, prevention, and treatment.
Figure 7: Scheme of the RA-RARA epigenetic mechanism of breast (cancer) epithelial cell fate (center). A. Physiological 
RA acts as the Janus bifrons god by regulating, in a spatiotemporal fashion, both the transcriptional RARA epigenetic function (chromatin 
changes at RARA-target genes, blue) and non-transcriptional RARA function to determine mammary epithelial cell fate decisions necessary 
for normal morphogenesis. B. Physiological RA promotes aberrant morphogenesis of mammary epithelial cells with epigenetic repression 
of RARA-target genes due to inhibition of RARA transcriptional function (┴) by activating non-transcriptional RARA. C. Differential 
susceptibility to physiological RA cancer-promoting action between breast cancer cell populations with increasing degree of inhibition 
of RARA transcriptional epigenetic functionality, mild (┴) or severe (┴), depends on the heterogeneity of RA synthesis by ALDH. D. 
Differential susceptibility to either anticancer or cancer-promoting actions of low/high supraphysiological RA treatment also depends on 
the cell-context specific degree of RARA transcriptional epigenetic functionality.
Oncotarget87077www.impactjournals.com/oncotarget
MATERIALS AND METHODS
Detailed Materials and Methods are described in the 
Supplementary Information.
Cells
T47D, HME1, and MCF7 clonal lines were 
developed by stable transfection and in part described in 
previous studies [18, 29, 32, 37]. RARA knock down in 
T47D403 cells was performed by stable transfection with 
pSuper-shRARA. GFP clonal lines were generated by 
stable transfection with a 3X-RARE-d2EGFP construct. 
T47D403-RFP cells were developed by stable transfection of 
T47D403 with pDsRed2-C1. Cell line identity was checked 
by short tandem repeat (STR) analysis and/or detection of 
transfected plasmids by PCR.
Drug treatments
Unless otherwise specified, treatments in 2D culture 
were performed for 72h. For P-AKT induction, treatments 
were performed in serum-free medium for 1h on starved 
cells. Treatments in 3D culture were performed in growth 
medium plus 2% Matrigel.
Quantitative RT-PCR
Transcript levels were analyzed by real time PCR 
with SybrGreen, and quantified by the Delta-deltaCt 
method using GAPDH for normalization.
Luciferase assay
Luciferase assays were performed by using Dual 
Glow Luciferase assay on cells transiently transfected 
with CAGA-luciferase, using renilla luciferase for 
normalization.
Protein analysis
Western blot was performed according to standard 
protocols using anti-P-AKT(Ser473), anti-RARA, anti-
actin, or anti-GAPDH antibodies. Protein bands were 
quantified with Image J (NIH).
Analysis of cell proliferation, migration, 
invasion, and stress fibers
Cell proliferation was assessed by colony formation 
assay in 2D culture, and EdU incorporation followed by 
confocal analysis in 3D acini. Cell migration and invasion 
were assessed by wound assay and Boyden chamber 
assay, respectively. Actin stress fibers were visualized with 
rhodamine-conjugated phalloidin.
Confocal imaging of 3D morphogenesis
Cells grown in three-dimensional (3D) culture 
on reconstituted basement membrane (Matrigel) were 
analyzed at different 3D stages by immunocytochemistry 
followed by confocal microscopy as described [18, 29].
Global gene expression and bioinformatics 
analysis
Global gene expression at different 3D stages of 
HME1 morphogenesis was assessed by RNA-sequencing. 
Gene clusters were identified based on [49]. Pathway 
enrichment analysis was performed with Metacore. Global 
gene expression in T47D cells was assessed by Affymetrix 
microarrays. RARA-target genes were identified based 
on [64, 65]. Data were deposited in Gene Expression 
Omnibus (GEO) (accession number GSE57119).
In vivo studies
Cells were injected subcutaneously in the flank 
region or in the mammary fat pad of female athymic NCr-
nu/nu mice fed either a control diet or a RA-containing 
AIN-93G diet. For metastasis analysis, 6 weeks after 
xenograft tumor removal, mice were euthanized 
and analyzed for the presence of RFP-positive cells. 
Experiments were pre-approved by the RPCI Animal Care 
and Use Committee.
Statistical analysis
For in vitro experiments, the group means were 
compared by Student’s t-test to determine significance. 
The effect of transcriptional/non-transcriptional RARA 
signaling pathways on cell growth was assessed by 
Standard Linear Regression. In vivo data were analyzed by 
one-way ANOVA, followed by multiple comparison tests.
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